載入中
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
前收盤價
US$15.67
+US$0.31 · +2.02%
盤後
US$15.56
−US$0.11 · -0.70%
10月12日 下午7:38 ET
盤中時間採用ET。市場資料可能有所延遲。
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
日內區間
目前US$15.67
52週區間
目前US$15.67
盤中時間採用ET。市場資料可能有所延遲。
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
日內區間
目前US$15.67
52週區間
目前US$15.67
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 8523.1萬 USD | 3720.5萬 USD | 206.5萬 USD | 271.9萬 USD | 355.5萬 USD |
| 銷貨成本 | 1179.7萬 USD | 618.8萬 USD | 63.5萬 USD | 68.6萬 USD | 67.1萬 USD |
| 毛利 | 7343.4萬 USD | 3101.7萬 USD | 143萬 USD | 203.3萬 USD | 288.4萬 USD |
| 研究與開發 | 2924.6萬 USD | 1387.4萬 USD | 1750.2萬 USD | 1858.3萬 USD | 1377.8萬 USD |
| 銷售、一般及管理費用 | 4352.8萬 USD | 2955.3萬 USD | 2211萬 USD | 1730.3萬 USD | 1363.7萬 USD |
| 營業費用 | 7277.4萬 USD | 4342.7萬 USD | 3961.2萬 USD | 3588.6萬 USD | 2741.5萬 USD |
| 利息收入 | 292萬 USD | 12.5萬 USD | — | — | — |
| 利息支出 | — | — | 143.9萬 USD | 268.5萬 USD | 118.6萬 USD |
| 折舊和攤銷 | 34.9萬 USD | 22.9萬 USD | 12.8萬 USD | 13.2萬 USD | 14.6萬 USD |
| 營業利益 | 66萬 USD | −1241萬 USD | −3818.2萬 USD | −3385.3萬 USD | −2453.1萬 USD |
| 淨利 | 270萬 USD | −2638.6萬 USD | −4767.8萬 USD | −3650.8萬 USD | −2564.9萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2019年12月24日 | 1:700 | — | — |
股票分割 | 2019年10月22日 | 1:100 | — | — |
股票分割 | 2018年5月2日 | 1:500 | — | — |
股票分割 | 2017年11月6日 | 1:350 | — | — |
股票分割 | 2016年7月21日 | 1:16 | — | — |
股票分割 | 2014年4月9日 | 1:16 | — | — |
已生效 2019年12月24日
1:700
已生效 2019年10月22日
1:100
已生效 2018年5月2日
1:500
已生效 2017年11月6日
1:350
已生效 2016年7月21日
1:16
已生效 2014年4月9日
1:16
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1463.97萬0.00%2.3兆 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM1153.52萬0.01%787.4億 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF502.8萬0.01%954億 USD0.05%US$233.52-0.63%
Simplify Propel Opportunities ETFSURI353.46萬4.68%7606.44萬 USD2.82%US$17.2565+0.23%
Vanguard Russell 2000 ETFVTWO272.23萬0.01%180億 USD0.06%US$112.27-0.35%
Dimensional - US Small Cap ETFDFAS189萬0.01%338.69億 USD0.31%US$78.17-0.23%
State Street SPDR S&P Health Care Equipment ETFXHE152.13萬0.87%1.74億 USD0.35%US$90.87+1.59%
iShares Micro-Cap ETFIWC139.56萬0.11%13.17億 USD0.60%US$181.66-0.73%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFSimplify Propel Opportunities ETFSURIVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASState Street SPDR S&P Health Care Equipment ETFXHEiShares Micro-Cap ETFIWCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
